How Tesamorelin works: the mechanism

Tesamorelin is a synthetic peptide that mimics a hormone your brain already makes. It is FDA-approved in the United States under the brand name Egrifta for a specific condition called HIV-associated lipodystrophy^[1]. This article walks through how it works, from the receptor it targets to the fat-metabolism effects downstream, in plain language.

Start here: what GHRH actually does

Your hypothalamus (a small region at the base of the brain that coordinates many hormones) releases a signalling molecule called growth hormone-releasing hormone, or GHRH. GHRH travels a short distance to the pituitary gland, a pea-sized structure sitting just below the hypothalamus. The pituitary contains specialised cells called somatotrophs. When GHRH arrives and binds to its receptor on those cells, the somatotrophs respond by releasing pulses of growth hormone (GH) into the bloodstream.

Those GH pulses do not last long. Natural GHRH itself is broken down within a few minutes by an enzyme called dipeptidyl peptidase IV (DPP-IV), which clips the molecule at its N-terminal end (the amino-acid end of the chain that the receptor needs to recognise). The result is that GHRH has a very short working window.

What makes tesamorelin different from natural GHRH

Tesamorelin is built from the same 44-amino-acid sequence as human GHRH, but with one addition: a hexenoyl group (a six-carbon chain with a double bond at the third position) attached to the N-terminal tyrosine^[1]. That small chemical addition blocks the spot where DPP-IV normally cuts, making the molecule more resistant to breakdown. The upshot is a longer working window while the core receptor-binding sequence stays intact.

Despite the modification, the FDA label confirms that tesamorelin binds and stimulates the GRF (growth hormone-releasing factor) receptor with similar potency to endogenous GHRH^[1]. It does not inject exogenous GH directly. Instead, it prompts the pituitary to release GH on its own, in a pattern that loosely follows normal physiological pulses.

The downstream chain: GH to IGF-1 to fat cells

Once GH pulses enter the circulation, they act on multiple cell types. Of particular relevance here: hepatocytes (liver cells) receive GH signals and respond by producing insulin-like growth factor 1 (IGF-1), a protein that carries out many of the tissue-building and metabolic effects that people associate with GH. The label notes that some effects are primarily mediated by IGF-1 produced in the liver and peripheral tissues, while others are driven by GH directly^[1].

The fat-reducing effect in lipodystrophy patients is mainly a direct GH action on adipocytes (fat cells). GH is lipolytic, meaning it promotes the breakdown of stored fat. Visceral fat (the fat that accumulates around organs inside the abdomen) is particularly responsive to GH signals, more so than subcutaneous fat (the fat just under the skin). In HIV-associated lipodystrophy, antiretroviral drugs disrupt normal fat distribution and GH pulsatility, leading to excess visceral fat. Tesamorelin is intended to restore some of that GH signalling and, through it, reduce visceral fat accumulation.

Why HIV lipodystrophy, specifically

HIV-associated lipodystrophy is characterised by abnormal fat redistribution: visceral fat accumulates while fat may be lost from the face, limbs, and buttocks. The condition is linked to older antiretroviral regimens, though it persists in some patients on modern therapies. Tesamorelin received FDA approval in November 2010 for this indication after two 26-week phase 3 trials showed it reduced visceral adipose tissue^[3]. Its approval is narrow: it is not approved for general weight loss or body recomposition outside that specific setting.

The IGF-1 concern: what regulators said

Tesamorelin reliably raises IGF-1 levels, and that is where regulatory caution enters the picture. When Egrifta's manufacturer applied for marketing authorisation in Europe, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) identified elevated IGF-1 as a major safety concern. The committee noted that high IGF-1 levels may be associated with an increased risk of cancer and potential worsening of diabetic eye disease^[2]. The application was withdrawn in June 2012 after the CHMP indicated that the data did not allow a positive benefit-risk conclusion, and tesamorelin has no European marketing authorisation.

The FDA reached a different conclusion for the specific HIV lipodystrophy context, where the visceral fat burden itself carries cardiovascular risk and the target population is well-defined. That benefit-risk calculation does not generalise to off-label use in healthy individuals, where the visceral fat burden and baseline IGF-1 picture are entirely different.

What this article does not cover

The full tesamorelin peptide page covers regulatory status by country, supply-chain considerations, and the available clinical safety data. The regulation section breaks down which jurisdictions have approved it and which have not. This article addresses mechanism only. If you are considering tesamorelin for any purpose, that conversation belongs with a clinician who can assess your individual risk factors, including your baseline IGF-1 and any cancer history.

This article is for educational purposes only and does not constitute medical advice. Tesamorelin is a prescription medicine in the United States, is not approved in the EU or UK, and should only be used under medical supervision.